- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05368454
Evaluation of a Digital Diabetes Self-Management Education and Support Program
Randomized Controlled Trial to Evaluate the Efficacy of an Integrated Lifestyle Management Solution With Continuous Glucose Monitoring for Type 2 Diabetes
Study Overview
Status
Conditions
Detailed Description
Type 2 diabetes (T2D) contributes substantially to morbidity and mortality in the US. Lifestyle management is a fundamental component of care for T2D. This includes self-management education and support, medical nutrition therapy, physical activity, smoking cessation counseling, and psychosocial care for the person with diabetes. Diabetes self-management education and support (DSMES) specifically pertains to helping people acquire the knowledge, skills, and ability for diabetes self-care, and assisting people to engage in the health-related behaviors needed to manage this condition on an ongoing basis. Research has shown that DSMES programs that target behavioral changes with intensive counseling and support lead to improved glucose control.
In recent years, technology-enabled platforms have been developed to deliver self-management support and education virtually, and commercial products are common. These platforms allow people with chronic diseases to access self-management support and education through their personal mobile devices (e.g., smartphones, tablets, laptops) and eliminate the need to travel to physical facilities for diabetes education sessions. The increased convenience brings potential to increase access, availability, and acceptability.
The development of Continuous Glucose Monitoring (CGM) has further advanced care and management of T2D. In particular, real-time CGM allows the person to view real-time glucose readings and patterns over time, without the need for painful finger sticks. While the majority of studies of CGM have been conducted with people with T2Ds using insulin, some clinical trials have shown that the use of real-time CGM is associated with improvements in glycemic control in people with T2D not using insulin.
The current standards of care for diabetes recommend CGM use for people with Type 1 and 2 diabetes when it is coupled with "robust diabetes education, training and support". However, there is a lack of well-integrated solutions that combine the potential benefit of both digitally delivered DSMES and CGM in a seamless way. Therefore, the purpose of this study is to examine the efficacy of a novel integrated solution of a digitally delivered T2D self-management education and support program with a continuous glucose monitor (CGM) built into the digital platform. The randomized control trial will test the impact of the novel solution for improving HbA1c and related CGM-derived outcomes and relevant diabetes management outcomes over six months related to the current standard of care.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Mateo, California, United States, 94401
- Evidation Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA
- 18 years or older
- Lives in the United States and has a valid mailing address
- Speaks, reads, and understands English as the primary language
- Be willing and able to provide written, signed, and dated informed consent
- Has a self-reported diagnosis of type 2 diabetes prior to enrollment for at least 6 months
- Self-reports HbA1c value ≥8.0% from most recent test taken within the past 6 months
Treatment regimen includes diet and exercise alone, oral glucose lowering medication, non-insulin injectable medications, basal insulin and/or combination of basal insulin plus oral medications. No more than 15% of the total sample may be on combination basal insulin/oral medication.
a. If the regimen is basal insulin with oral medications, the participant must have initiated basal insulin in addition to oral medication at least 6 months prior to enrollment.
- Currently on medication regimen for at least 3 months prior to enrollment
- HbA1c greater than or equal to 8.0% as demonstrated by laboratory HbA1c at secondary screening
- Has a compatible smartphone running either Android OS 5.0 or higher, or iPhone 7 or later, running iOS 11 or higher with an on-going data plan
- Is willing to set up an online account using the Omada Health Program/app and LibreLink app, and agree to share their CGM data with designated health care providers connected to the study.
- Must be willing to complete all study tasks as specified by the protocol
- Must report being compliant with their diabetes management plan and must be willing to adhere to their medication regimen throughout the study.
- Not currently in another clinical trial
EXCLUSION CRITERIA
- Type 1 diabetes or a history of diabetic ketoacidosis
- Self-reported HbA1c < 8.0% or does not know their HbA1c level
- Self-reported condition leading to life expectancy < 12 months
- Pregnant, is attempting to conceive or is not willing and able to practice birth control during the study duration (applicable to female participants who are able to become pregnant only)
- Currently has self-reported skin lesions, scarring, redness, infection or edema at the application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. This includes known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin
- Has X-ray, MRI or CT appointment scheduled during the study periods of CGM measurement with the FreeStyle Libre Pro, and the appointment(s) cannot be rescheduled
- Currently using mealtime bolus injections of insulin, premixed insulin formulations or a continuous subcutaneous infusion of insulin
- Visual impairment that would prohibit ability to view sensor data or use the Omada platform
Has had any of the following in the past 3 months:
- Transient ischemic attack or stroke
- Heart attack (myocardial infarction)
- Hospitalization for congestive heart failure
- Cardiac surgery (such as coronary artery bypass grafting (CABG), coronary artery stenting)
- If it has been > 3 months since any of the above, applicant must be medically cleared by their primary physician to exercise
- Bariatric/gastric bypass surgery, including gastric sleeve, gastric balloon within the past 6 months
- Participation in other research studies involving medication or device within 1 month prior to enrollment
- Organ transplant (kidney, liver, etc.) within the past 6 months
- Recent (within the last 6 months) or planned cancer treatment (chemotherapy, radiation, bone marrow transplant, cancer-related surgery - not including hormonal chemotherapy, such as tamoxifen)
- Self-reported renal impairment, defined as estimated glomerular filtration rate <30 mL/min/1.73 m2
- Language barriers precluding comprehension of study activities and informed consent 16. Currently on a routine regimen of glucocorticoids or psychotropic medications 17. Self-reported alcohol or substance abuse issue or dependency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard of Care
|
All participants randomized to the standard of care/control arm will be asked to continue with their current care plan and care team for management of their diabetes.
|
Experimental: Integrated Solution
|
An online program for Diabetes Self-Management, Education and Support (DSMES) that includes personal coaching by a certified Diabetes Care and Education Specialist (CDCES), tracking tools, and FreeStyle Libre CGMs, a wearable sensor with data scanning ability accessed through the smartphone app.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c
Time Frame: Baseline, 3 months, 6 months
|
Non-fasting venous blood sample
|
Baseline, 3 months, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in daily Time in Range [70-180] mg/dL
Time Frame: Baseline, 3 months, 6 months
|
Derived from continuous glucose monitor
|
Baseline, 3 months, 6 months
|
Change in body weight
Time Frame: Baseline, 3 months, 6 months
|
Measured with a digital weight scale in stocking feet
|
Baseline, 3 months, 6 months
|
Change in resting blood pressure
Time Frame: Baseline, 3 months, 6 months
|
Collected with an automated, calibrated blood pressure monitor with self-inflating cuff
|
Baseline, 3 months, 6 months
|
Change in diabetes distress
Time Frame: Baseline, 3 months, 6 months
|
The Diabetes Distress Scale, a 17-item self-report questionnaire, that captures four dimensions: emotional burden, regimen distress, interpersonal distress and physician distress related to diabetes and diabetes self-care
|
Baseline, 3 months, 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sarah Linke, PhD, Omada Health, Inc.
- Principal Investigator: David Kerr, MBChB, DM, FRCPE, Evidation Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022 V 5.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Online Diabetes Self-Management Education and Support (DSMES) Program
-
Omada Health, Inc.Palo Alto Medical Foundation; Sutter HealthTerminatedType 2 DiabetesUnited States
-
NYU Langone HealthAgency for Healthcare Research and Quality (AHRQ)Not yet recruitingType 2 DiabetesUnited States
-
NYU Langone HealthNational Institute on Minority Health and Health Disparities (NIMHD)Not yet recruitingType 2 DiabetesUnited States
-
University of ArizonaRecruiting
-
Sinai Health SystemRecruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Diabetes Mellitus, Type 1United States
-
University of ArkansasPatient-Centered Outcomes Research InstituteActive, not recruitingDiabetes Mellitus, Type 2United States
-
University of MichiganRecruiting
-
University of ArkansasNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
University of MichiganNational Institutes of Health (NIH); National Institute on Aging (NIA); Blue...Completed
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedHypertension | Diabetes Mellitus | High Blood Pressure | High Blood SugarUnited States